{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:20:16Z","timestamp":1791062416849,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005112","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000}}],"reference-count":52,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005112.pub2","type":"journal-article","created":{"date-parts":[[2006,8,11]],"date-time":"2006-08-11T00:59:30Z","timestamp":1155257970000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis"],"prefix":"10.1002","author":[{"given":"Maureen M","family":"Lawson","sequence":"first","affiliation":[{"name":"Central Manchester and Manchester Children's University Hospitals; Department of Paediatric Gastroenterology; Booth Hall Children's Hospital Charlestown Road, Blakley Manchester UK M9 7AA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G","family":"Thomas","sequence":"additional","affiliation":[{"name":"Booth Hall Childrens Hospital; Charlestown Road Blackley Manchester UK M9 7AA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K","family":"Akobeng","sequence":"additional","affiliation":[{"name":"Royal Manchester Children's Hospital; Oxford Road Manchester UK M13 9WL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD005112.pub2-BIB0001|cit1","first-page":"231","article-title":"Infliximab in the treatment of steroid-dependent ulcerative colitis","volume":"8","author":"Armuzzi","year":"2004","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"10.1002\/14651858.CD005112.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD005112.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00042737-200411000-00014","article-title":"Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study","volume":"16","author":"Ochsenkuhn","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1002\/14651858.CD005112.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistent ulcerative colitis: a randomised controlled trial","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"issue":"23","key":"10.1002\/14651858.CD005112.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1002\/14651858.CD005112.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/14651858.CD005112.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1002\/14651858.CD005112.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1590-8658(02)80205-5","article-title":"Infliximab for treatment of steroid-refractory ulcerative colitis","volume":"34","author":"Actis","year":"2002","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1002\/14651858.CD005112.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4321\/S1130-01082004000200002","article-title":"Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis","volume":"96","author":"Bermejo","year":"2004","journal-title":"Rev Esp Enferm Dig"},{"issue":"6","key":"10.1002\/14651858.CD005112.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD005112.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ibd.3780070507","article-title":"Infliximab for patients with refractory ulcerative colitis","volume":"7 Suppl 1","author":"Chey","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1002\/14651858.CD005112.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.dld.2003.04.001","article-title":"Outcome of a conservative approach in severe ulcerative colitis","volume":"36","author":"Daperno","year":"2004","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1002\/14651858.CD005112.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1046\/j.1365-2036.1997.00251.x","article-title":"Treatment of ulcerative colitis with an engineered human anti-TNF alpha antibody CDP571","volume":"11","author":"Evans","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD005112.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.2003.01686.x","article-title":"Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study","volume":"18","author":"Gornet","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"23-24","key":"10.1002\/14651858.CD005112.pub2-BIB0015|cit15","first-page":"930","article-title":"Infliximab in severe steroid-refractory ulcerative colitis: a pilot study","volume":"113","author":"Kaser","year":"2001","journal-title":"Wien Klin Wochenschr"},{"issue":"9","key":"10.1002\/14651858.CD005112.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1590-8658(02)80204-3","article-title":"Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients","volume":"34","author":"Kohn","year":"2002","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1002\/14651858.CD005112.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00054725-200105000-00002","article-title":"Is infliximab effective for induction of remission in patients with ulcerative colitis?","volume":"7","author":"Lichtenstein","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1002\/14651858.CD005112.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005176-200203000-00017","article-title":"Infliximab as a novel therapy for pediatric ulcerative colitis","volume":"34","author":"Mamula","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1002\/14651858.CD005112.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1590-8658(04)00088-X","article-title":"The use of the anti-tumour necrosis factor monoclonal antibody -- infliximab -- to treat ulcerative colitis: implications and trends beyond the available data","volume":"36","author":"Rossetti","year":"2004","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1002\/14651858.CD005112.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0210-5705(03)70494-4","article-title":"Infliximab as treatment for a severe outbreak of ulcerative colitis","volume":"27","author":"Ruiz","year":"2004","journal-title":"Gastroenterol Hepatol"},{"key":"10.1002\/14651858.CD005112.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"29C","DOI":"10.1155\/2000\/698523","article-title":"Long term safety of infliximab","volume":"14 (Suppl C)","author":"Schaible","year":"2000","journal-title":"Can J Gastroenterol"},{"issue":"7-8","key":"10.1002\/14651858.CD005112.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1345\/aph.10395","article-title":"Use of infliximab in pediatric patients with inflammatory bowel disease","volume":"35","author":"Serrano","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1002\/14651858.CD005112.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/j.1572-0241.2002.06026.x","article-title":"Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis","volume":"97","author":"Su","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1002\/14651858.CD005112.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1046\/j.1365-2036.2003.01535.x","article-title":"Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis","volume":"17","author":"Viscido","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"Issue 4","key":"10.1002\/14651858.CD005112.pub2-BIB0025|cit25","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","author":"Akobeng","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005112.pub2-BIB0026|cit26","unstructured":"Alderson P Green S Higgens JPT Assessment of study quality. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Section 6. In: The Cochrane Library, Issue 1, 2004 Chichester UK: John Wiley & Sons, Ltd"},{"issue":"5375","key":"10.1002\/14651858.CD005112.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bmj.1.5375.89","article-title":"Variation between observers in describing mucosal appearances in proctocolitis","volume":"1","author":"Baron","year":"1964","journal-title":"Br Med J"},{"issue":"6","key":"10.1002\/14651858.CD005112.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD005112.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005112.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ibd.3780070507","article-title":"Infliximab for patients with refractory ulcerative colitis","volume":"7","author":"Chey","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1002\/14651858.CD005112.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1572-0241.2001.04039.x","article-title":"Infliximab for refractory ulcerative colitis","volume":"96","author":"Chey","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD005112.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2036.2003.01411.x","article-title":"Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model","volume":"17","author":"Crandall","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"7414","key":"10.1002\/14651858.CD005112.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD005112.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00054725-200203000-00002","article-title":"Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital","volume":"8","author":"Hommes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1002\/14651858.CD005112.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1067\/mpd.2000.107161","article-title":"Use of infliximab in the treatment of Crohn's disease in children and adolescents","volume":"137","author":"Hyams","year":"2000","journal-title":"J Pediatr"},{"issue":"1","key":"10.1002\/14651858.CD005112.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"15","key":"10.1002\/14651858.CD005112.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/14651858.CD005112.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1590-8658(02)80204-3","article-title":"Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients","volume":"34","author":"Kohn","year":"2002","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1002\/14651858.CD005112.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1572-0241.2002.05784.x","article-title":"Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction","volume":"97","author":"Kugathasan","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1002\/14651858.CD005112.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD005112.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease","volume":"32","author":"Murch","year":"1991","journal-title":"Gut"},{"issue":"12","key":"10.1002\/14651858.CD005112.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jama.281.12.1110","article-title":"Accuracy of data in abstracts of published research articles","volume":"281","author":"Pitkin","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD005112.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/gut.39.5.684","article-title":"Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease","volume":"39","author":"Reimund","year":"1996","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD005112.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD005112.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1002\/14651858.CD005112.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1002\/14651858.CD005112.pub2-BIB0047|cit47","first-page":"971","article-title":"An index of disease activity in patients with ulcerative colitis","volume":"87","author":"Seo","year":"1992","journal-title":"Am J Gastroenterol"},{"issue":"9051","key":"10.1002\/14651858.CD005112.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD005112.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","article-title":"Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center","volume":"98","author":"Stephens","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"7249","key":"10.1002\/14651858.CD005112.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1136\/bmj.320.7249.1574","article-title":"Empirical assessment of effect of publication bias on meta-analyses","volume":"320","author":"Sutton","year":"2000","journal-title":"BMJ"},{"issue":"15","key":"10.1002\/14651858.CD005112.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"issue":"4884","key":"10.1002\/14651858.CD005112.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in ulcerative colitis; preliminary report on a therapeutic trial","volume":"2","author":"Truelove","year":"1954","journal-title":"Br Med J"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD005112.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:45:05Z","timestamp":1628545505000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005112.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2006,7,19]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005112.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,19]]}}}